GW Pharmaceuticals to Present at the Leerink Partners 5th Annual Global Healthcare Conference
February 04 2016 - 10:45AM
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the
Company”), a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its
proprietary cannabinoid product platform, today announced that
Justin Gover, GW’s Chief Executive Officer, will present at the
Leerink Partners 5th Annual Global Healthcare Conference to be held
at the Waldorf Astoria Hotel in New York City on Wednesday, 10
February at 11:05 a.m. EST.
A live audio webcast of the presentation will be
available through GW’s corporate website in the investor relations
section from the investor’s calendar of events page at
www.gwpharm.com. A replay will be available soon after the live
presentation.
About GW Pharmaceuticals
plc
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW commercialized the
world’s first plant-derived cannabinoid prescription drug,
Sativex®, which is approved for the treatment of spasticity due to
multiple sclerosis in 28 countries outside the United States. GW is
advancing an orphan drug program in the field of childhood epilepsy
with a focus on Epidiolex® (cannabidiol), which is in Phase 3
clinical development for the treatment of Dravet syndrome and
Lennox-Gastaut syndrome and which is also expected to enter Phase 3
clinical trials in the treatment of Tuberous Sclerosis Complex. GW
has a deep pipeline of additional cannabinoid product candidates
which includes Sativex in Phase 3 clinical development as a
potential treatment of pain associated with advanced cancer, as
well as compounds in Phase 1 and 2 trials for glioma, type 2
diabetes, and schizophrenia. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
(Today) +44 20 3727 1000 |
Stephen
Schultz, VP Investor Relations (U.S.)
|
917 280
2424 / 401 500 6570 |
|
|
FTI Consulting (Media Enquiries) |
|
Ben
Atwell / Simon Conway |
+44 20
3727 1000 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024